Literature DB >> 28920322

Treatment for recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma: A single institution experience.

Tatsuro Okamoto1, Tokujiro Yano1, Akira Haro1, Tsukihisa Yoshida1, Mikihiro Kohno1, Yoshihiko Maehara1.   

Abstract

BACKGROUND: Malignant pleural mesothelioma (MPM) is a relatively rare, aggressive neoplasm associated with asbestos exposure. Extrapleural pneumonectomy (EPP) is often performed for resectable MPM as part of a multidisciplinary treatment; however, available data on treatments for recurrence after EPP are limited.
METHODS: The clinical records of consecutive MPM patients who underwent EPP at our institution from 2001 to 2010 were retrospectively reviewed. There were 10 patients who underwent EPP with or without perioperative chemotherapy; of these, recurrence was observed in eight patients.
RESULTS: The overall median survival time and time to recurrence were 49.6 months and 15.4 months, respectively, after EPP. The first recurrence occurred within the ipsilateral thorax in four patients. These patients all underwent local treatments for their recurrence, including surgery or radiotherapy and with or without systemic chemotherapy. Other first recurrences were seen in the peritoneal space of two patients and in the contralateral lung of two patients. These patients received platinum-based systemic chemotherapy for their recurrence. The median survival time after the first recurrence was 17.8 months, and the 2-year survival rate was 23.4%.
CONCLUSIONS: Most patients who underwent EPP developed tumor recurrences. Direct tumor extension may be a major mechanism of recurrence. Aggressive treatment for recurrent MPM after EPP, including locoregional control and/or systemic chemotherapy, was important for achieving long-term survival.
© 2012 Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  extrapleural pneumonectomy; malignant pleural mesothelioma; radiotherapy; recurrence; surgery

Year:  2013        PMID: 28920322     DOI: 10.1111/j.1759-7714.2012.00138.x

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  4 in total

1.  Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.

Authors:  Tetsuzo Tagawa; Masaki Anraku; Yosuke Morodomi; Tomoyoshi Takenaka; Tatsuro Okamoto; Mitsuhiro Takenoyama; Yukito Ichinose; Yoshihiko Maehara; B C John Cho; Ronald Feld; Ming-Sound Tsao; Natasha Leighl; Andrea Bezjak; Shaf Keshavjee; Marc de Perrot
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

Review 2.  Second Surgery for Recurrent Malignant Pleural Mesothelioma after Multimodality Treatment: A Systematic Review.

Authors:  Alice Bellini; Sara Mazzarra; Sara Sterrantino; Desideria Argnani; Franco Stella
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

3.  Salvage debulking surgery and hyperthermic intrathoracic chemotherapy for massive recurrent mesothelioma in the mediastinum.

Authors:  Shi Sum Poon; Caterina Alberti; Marco Nardini; Marcello Migliore
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-06-15

4.  Relapse Patterns and Tailored Treatment Strategies for Malignant Pleural Mesothelioma Recurrence after Multimodality Therapy.

Authors:  Alice Bellini; Andrea Dell'Amore; Stefano Terzi; Giovanni Zambello; Andrea Zuin; Giulia Pasello; Fiorella Calabrese; Marco Schiavon; Federico Rea
Journal:  J Clin Med       Date:  2021-03-08       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.